EXoZymes Inc EXOZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Investor Summit | MicroCap Opportunities to Watch - August 26
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Trading Information
- Previous Close Price
- $4.31
- Day Range
- $4.19–4.20
- 52-Week Range
- $3.74–16.50
- Bid/Ask
- $4.24 / $4.80
- Shares Outstanding
- 9.30M
- Market Cap
- $38.24M
- Volume/Avg
- 7,456 / 8,408
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 32
- Website
- https://www.exozymes.com
Valuation
Metric | EXOZ |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.44 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | EXOZ |
|---|---|
Quick Ratio | 3.63 |
Current Ratio | 3.81 |
Interest Coverage | — |
Quick Ratio
EXOZ
Profitability
Metric | EXOZ |
|---|---|
Return on Assets (Normalized) | −105.44% |
Return on Equity (Normalized) | −176.00% |
Return on Invested Capital (Normalized) | −139.86% |
Return on Assets
EXOZ
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|FkQ#Z?$ | LOCK|RVs> | $138B | |||
| Moderna Inc MRNA | LOCK|?<@BG^ | LOCK|Psp | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|x#v>v$ | LOCK|#N^g> | $93B | |||
| argenx SE ADR ARGX | LOCK|zd&TxW | LOCK|l! | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|VF!#F^< | LOCK|FT | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!?!S&Z& | LOCK|Hy@yt | $30B | |||
| Incyte Corp INCY | LOCK|<B<?%js | LOCK|tj | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%by%<b | LOCK|&v | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%WmKJS | LOCK|$c!! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|D%Y#dwG | LOCK|?$w | $15B |
United States